Ferric carboxymaltose: A review of its use in iron-deficiency anaemia

Drugs

Volumn 69, Issue 6, 2009, Pages 739-756

  Lyseng Williamson, Katherine A ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FERINJECT; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; IRON; IRON COMPLEX; IRON DEXTRAN; TRANSFERRIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLACTIC SHOCK; AREA UNDER THE CURVE; BLOOD TRANSFUSION; BRONCHITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FECES COLOR; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; INJECTION SITE REACTION; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON DEPLETION; NAUSEA; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; URTICARIA; UTERUS BLEEDING; VOMITING;

ANEMIA, IRON-DEFICIENCY; FERRIC COMPOUNDS; HEMATINICS; HUMANS; MALTOSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 65949107825     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969060-00007     Document Type: Review

References (50)

1. World Health Organization. Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. Geneva: World Health Organization, 2001.
2. de Benoist B, McLean E, Egli I, et al. Worldwide prevalence of anaemia 1993-2005: WHO Global Database. Geneva: World Health Organization, 2008.
3. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008; 13 (4): 393-404.
4. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007; 13 (36): 4798-806.
5. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006 Dec; 24 (11-12): 1507-23.
6. Dodd J, Dare M, Middleton P. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev 2004; (4): CD004222.
7. Gisbert JP, Gomolló n F.Commonmisconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008 May; 103 (5): 1299-307.
8. Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenterol 2009; 25 (2): 122-8.
9. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. InflammBowelDis 2007; 13 (12): 1545-53.
10. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults: using iron agents [online]. Available from URL: http://www.kidney.org/ professionals/kdoqi/guidelines-anemia/cpr32.htm [Accessed 2009 Jan 22].
11. Madore F, White CT, Foley RN, et al. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int 2008 Aug; 74 Suppl. 110: S7-11.
12. National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease. NICE clinical guideline 39. London: National Institute for Health and Clinical Excellence, 2006 Sep.
13. Locatelli F, Pisoni RL, Combe C. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dialysis Transplant 2004; 19 (1): 121-32.
14. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008 Nov; 52 (5): 897-906.
15. Locatelli F, Aljama P, Bá rá ny P, et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Section III: treatment of renal anaemia. NephrolDial Transplant 2004May; 19 Suppl. 2: ii16-31.
16. UK Medicines and Healthcare Products Regulatory Agency. Public assessment report (decentralised procedure): Ferinject 50 mg iron/ml solution for injection/infusion (PL 15240/0002; UK/H/0894/001/DC) [online]. Available from URL: http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/ con014025.pdf [Accessed 2008 Dec 9].
17. Ferinject: UK summary of product characteristics. Purley: Syner-Med (Pharmaceutical Products) Ltd, 2007 Jul 17.
18. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject-): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009; 23 (1): 11-6.
19. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42 (12): 1439-52.
20. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am SocNephrol 2004 Dec; 15 Suppl. 2: S93-8.
21. Beshara S, Sö rensen J, Lubberink M, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003 Mar; 120 (5): 853-9.
22. Geisser P, Banké-Bochita J. The pharmacokinetics, safety and tolerability of ferric carboxymaltose: data from a dose escalating study in patients with iron deficiency anaemia [abstract no. MP382 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10-13; Stockholm.
23. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (Ferinject®) randomized controlled trial. Am J Gastroenterol 2008 May; 103 (5): 1182-92.
24. Gordon SS, Hadley PE, Van Wyck DB, et al. Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding [abstract]. Obstet Gynecol 2007 Apr; 109 (4 Suppl.): 108S.
25. Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008 Apr; 101 (1): 67-73.
26. Seid MH, Derman RJ, Baker JB, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008 Oct; 199 (4): 435.e1-7.
27. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007 Aug; 110 (2 Pt 1): 267-78.
28. Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD [abstract no. MO017 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10-13; Stockholm.
29. Schaefer RM, Khasabov NN, Todorov NG, et al. The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia [abstract no. MP375 plus poster]. 45th Congress of the European Renal Association and the European Dialysis and Transplant Association; 2008 May 10-13; Stockholm.
30. Agarwal R. Iron, oxidative stress, and clinical outcomes. Pediatr Nephrol 2008; 23 (8): 1195-9.
31. Toblli JE, Cao G, Oliveri L, et al. Evaluation of intravenous iron preparations on cardiovascular toxicity in normal rats [abstract no. PUB476]. American Society of Nephrology Renal Week; 2008 Nov 4-9; Philadelphia (PA).
32. Manley HJ, McClaran ML. Determination of VIT 45 (IND#63,243 American Regent) removal by closed loop in vitro hemodialysis system. Int J Artif Organs 2006 Nov; 29 (11): 1062-6.
33. Seid MH, Mangione A, Valaoras TG, et al. Safety profile of iron carboxymaltose, a new high dose intravenous iron in patients with iron deficiency anemia [abstract no. 3739]. Blood 2006 Nov 2; 108 (11 Pt 2): 8b.
34. Qunibi W, Dinh Q, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM): data from the FCM clinical program [abstract no. MP383 plus poster]. 45th Congress of the European Renal Association and the Ferric Carboxymaltose: European Dialysis and Transplant Association; 2008 May 10-13; Stockholm.
35. Vifor Pharma. Overview of the safety of Ferinject (ferric carboxymaltose, FCM) in the clinical trial programme. St Gallen, Switzerland; Vifor (International), Inc., 2009 Jan 19 (Data on file).
36. Lu M. Injectafer® (iron carboxymaltose injection):NDA 22-054: slide presentation [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/ 08/slides/2008-4337s1-05-FDA-Lu.ppt [Accessed 2008 Dec 11].
37. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Drug Safety and Risk Management Advisory Committee, February 1, 2008 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ ac/08/minutes/2008-4337m1-Final.pdf [Accessed 2008 Dec 11].
38. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Apr 16].
39. Tagboto S, Cropper L, Turner J, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject®) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care 2009 Mar; 35 (1): 18-23.
40. Grimmelt A-C, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009 Feb; 71 (2): 125-9.
41. European Medicines Agency. CosmoFer: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid=14139 [Accessed 2009 Jan 21].
42. European Medicines Agency. Venofer 20 mg/ml solution for injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=14438 [Accessed 2009 Jan 21].
43. Ferrlecit® (sodium ferric gluconate complex in sucrose injection): US product monograph. Corona (CA): Watson Pharma, Inc., 2003 Apr 13.
44. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006 Feb; 21 (2): 378-82.
45. Sengölge G, Hörl W, Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 2005 Dec; 35 Suppl. 3: 46-51.
46. Steiner S, Brock E, Schneider H, et al. Budget impact (BI) of parenteral iron treatment of iron deficiency anaemia (IDA) in Switzerland [abstract no. PHM2]. Value Health 2007 Nov; 10 (6): A280.
47. Littlewood TJ, Alikhan R. The use of intravenous iron in patients with cancer-related anaemia. Br J Haematol 2008; 141 (6): 751-6.
48. Ludwig H. Iron metabolism and iron supplementation in anemia of cancer. SeminHematol 2006 Oct; 43 (4 Suppl. 6): S13-7.
49. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008 Aug 12; 52 (7): 501-11.
50. Cavill I, Auerbach M, Bailie G, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006 Apr; 22 (4): 731-7.